Cyber-criminals often see healthcare firms’ shoddy protection as a “pot of gold.”
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
An increasing share of NBA endorsement deals has been spread among shoe firms fighting for a piece of Nike’s market share.
As China tightens its grip on rare earths exports, one of its most crucial bargaining chips, the global supply chain is showing cracks.
Snacks now make up around half of the historic soup company’s sales, up from less than a third a decade ago.
At the heart of the biotech deal is a relatively new drug technology called PD-1/VEGF bispecific antibodies.
The agreement comes as The New York Times continues to sue OpenAI and Microsoft for alleged copyright infringement.
Brands that cater to the uber wealthy saw a dip in sales for the first quarter of 2025, continuing a slowdown that started last year.
2025 is projected to be an unusually terrible year for the US travel industry — and only the US travel industry.
At less than three years old and with just ten products, Rhode is a rocket ship with $212 million in net sales last year.
While virtual care boomed during the pandemic, the sector more recently had an up-and-down couple of years as the world returned to normalcy.
The multinational automaking giant announced Wednesday that its Americas COO Antonio Filosa will soon sit in the driver’s seat.
The so-called “golden share” in US Steel would grant the US federal government a de facto veto over key decisions.
Luxury carmakers BMW and Mercedes are slipping behind little-known, home-grown Seres in the all-important China market.
The cable-dependent legacy media players spent the 2010s helping to sharpen the Netflix-issued cord-cutting clippers.
Moderna is counting on revenue from newer mRNA vaccines, including a next generation Covid shot, to make up for falling sales.
While the company didn’t mention the threat of tariffs, Nike is heavily exposed in China, home to roughly 24% of its suppliers.